Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants

Abstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity...

Full description

Bibliographic Details
Main Authors: Magnus Unemo, Marit Hansen, Ronza Hadad, Mirja Puolakkainen, Henrik Westh, Kaisu Rantakokko-Jalava, Carina Thilesen, Michelle J. Cole, Iryna Boiko, Pham T. Lan, Daniel Golparian, Shin Ito, Martin Sundqvist
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Infectious Diseases
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12879-020-05148-7
id doaj-55b92bfe41824b28a7f9b6e4bccd7553
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Magnus Unemo
Marit Hansen
Ronza Hadad
Mirja Puolakkainen
Henrik Westh
Kaisu Rantakokko-Jalava
Carina Thilesen
Michelle J. Cole
Iryna Boiko
Pham T. Lan
Daniel Golparian
Shin Ito
Martin Sundqvist
spellingShingle Magnus Unemo
Marit Hansen
Ronza Hadad
Mirja Puolakkainen
Henrik Westh
Kaisu Rantakokko-Jalava
Carina Thilesen
Michelle J. Cole
Iryna Boiko
Pham T. Lan
Daniel Golparian
Shin Ito
Martin Sundqvist
Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
BMC Infectious Diseases
Finnish new variant
Chlamydia trachomatis
Aptima combo 2
23S rRNA
Validation
Surveillance
author_facet Magnus Unemo
Marit Hansen
Ronza Hadad
Mirja Puolakkainen
Henrik Westh
Kaisu Rantakokko-Jalava
Carina Thilesen
Michelle J. Cole
Iryna Boiko
Pham T. Lan
Daniel Golparian
Shin Ito
Martin Sundqvist
author_sort Magnus Unemo
title Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
title_short Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
title_full Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
title_fullStr Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
title_full_unstemmed Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants
title_sort sensitivity, specificity, inclusivity and exclusivity of the updated aptima combo 2 assay, which provides detection coverage of the new diagnostic-escape chlamydia trachomatis variants
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2020-06-01
description Abstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity of the updated AC2 for the detection of CT and Neisseria gonorrhoeae (NG) on the automated Panther system (Hologic). Methods We examined 1004 clinical AC2 samples and 225 analytical samples spiked with phenotypically and/or genetically diverse NG and CT strains, and other potentially cross-reacting microbial species. The clinical AC2 samples included CT wild type (WT)-positive (n = 488), all four described AC2 diagnostic-escape nvCTs (n = 170), NG-positive (n = 214), and CT/NG-negative (n = 202) specimens. Results All nvCT-positive samples (100%) and 486 (99.6%) of the CT WT-positive samples were positive in the updated AC2. All NG-positive, CT/NG-negative, Trichomonas vaginalis (TV)-positive, bacterial vaginosis-positive, and Candida-positive AC2 specimens gave correct results. The clinical sensitivity and specificity of the updated AC2 for CT detection was 99.7 and 100%, respectively, and for NG detection was 100% for both. Examining spiked samples, the analytical inclusivity and exclusivity were 100%, i.e., in clinically relevant concentrations of spiked microbe. Conclusions The updated AC2, including two CT targets and one NG target, showed a high sensitivity, specificity, inclusivity and exclusivity for the detection of CT WT, nvCTs, and NG. The updated AC2 on the fully automated Panther system offers a simple, rapid, high-throughput, sensitive, and specific diagnosis of CT and NG, which can easily be combined with detection of Mycoplasma genitalium and TV.
topic Finnish new variant
Chlamydia trachomatis
Aptima combo 2
23S rRNA
Validation
Surveillance
url http://link.springer.com/article/10.1186/s12879-020-05148-7
work_keys_str_mv AT magnusunemo sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT marithansen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT ronzahadad sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT mirjapuolakkainen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT henrikwesth sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT kaisurantakokkojalava sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT carinathilesen sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT michellejcole sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT irynaboiko sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT phamtlan sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT danielgolparian sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT shinito sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
AT martinsundqvist sensitivityspecificityinclusivityandexclusivityoftheupdatedaptimacombo2assaywhichprovidesdetectioncoverageofthenewdiagnosticescapechlamydiatrachomatisvariants
_version_ 1724517682614632448
spelling doaj-55b92bfe41824b28a7f9b6e4bccd75532020-11-25T03:43:54ZengBMCBMC Infectious Diseases1471-23342020-06-012011610.1186/s12879-020-05148-7Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variantsMagnus Unemo0Marit Hansen1Ronza Hadad2Mirja Puolakkainen3Henrik Westh4Kaisu Rantakokko-Jalava5Carina Thilesen6Michelle J. Cole7Iryna Boiko8Pham T. Lan9Daniel Golparian10Shin Ito11Martin Sundqvist12World Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityDepartment of Virology and Immunology, University of Helsinki and Helsinki University Hospital, HUSLABDepartment of Clinical Medicine, Faculty of Medical Sciences, University of CopenhagenDepartment of Clinical Microbiology, Turku University HospitalDepartment of Microbiology, Unilabs Laboratory MedicineNational Infection Service, Public Health EnglandWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityHanoi Medical University, National Hospital of Dermatology and VenereologyWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityiClinicWorld Health Organization Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections (STIs), National Reference Laboratory for STIs, Department of Laboratory Medicine, Clinical Microbiology, Faculty of Medicine and Health, Örebro UniversityAbstract Background Four new variants of Chlamydia trachomatis (nvCTs), detected in several countries, cause false-negative or equivocal results using the Aptima Combo 2 assay (AC2; Hologic). We evaluated the clinical sensitivity and specificity, as well as the analytical inclusivity and exclusivity of the updated AC2 for the detection of CT and Neisseria gonorrhoeae (NG) on the automated Panther system (Hologic). Methods We examined 1004 clinical AC2 samples and 225 analytical samples spiked with phenotypically and/or genetically diverse NG and CT strains, and other potentially cross-reacting microbial species. The clinical AC2 samples included CT wild type (WT)-positive (n = 488), all four described AC2 diagnostic-escape nvCTs (n = 170), NG-positive (n = 214), and CT/NG-negative (n = 202) specimens. Results All nvCT-positive samples (100%) and 486 (99.6%) of the CT WT-positive samples were positive in the updated AC2. All NG-positive, CT/NG-negative, Trichomonas vaginalis (TV)-positive, bacterial vaginosis-positive, and Candida-positive AC2 specimens gave correct results. The clinical sensitivity and specificity of the updated AC2 for CT detection was 99.7 and 100%, respectively, and for NG detection was 100% for both. Examining spiked samples, the analytical inclusivity and exclusivity were 100%, i.e., in clinically relevant concentrations of spiked microbe. Conclusions The updated AC2, including two CT targets and one NG target, showed a high sensitivity, specificity, inclusivity and exclusivity for the detection of CT WT, nvCTs, and NG. The updated AC2 on the fully automated Panther system offers a simple, rapid, high-throughput, sensitive, and specific diagnosis of CT and NG, which can easily be combined with detection of Mycoplasma genitalium and TV.http://link.springer.com/article/10.1186/s12879-020-05148-7Finnish new variantChlamydia trachomatisAptima combo 223S rRNAValidationSurveillance